Cerus 2025 Q2 Earnings Revenue Rises 19% as Net Loss Narrows Slightly

Cerus reported mixed results in its fiscal 2025 Q2 earnings on August 6, 2025, with revenue growth outpacing expectations, though losses remained negative. The company raised its full-year product revenue guidance and highlighted strong commercial performance from its INTERCEPT portfolio.

Revenue
Cerus achieved a 19.0% year-over-year increase in total revenue, reaching $60.13 million in the second quarter of 2025, compared to $50.52 million in the same period in 2024. The revenue increase was driven by robust product sales of $52.45 million, supported by $7.68 million in government contract revenue, reflecting the ongoing adoption of its INTERCEPT technology in blood safety solutions.

Earnings/Net Income
The company maintained an EPS of $-0.03 for Q2 2025, consistent with the prior year, and reported a narrowed net loss of $-5.71 million, a 1.0% reduction from the $-5.78 million net loss in Q2 2024, signaling early progress in cost control and operational efficiency.

Price Action
Following the earnings release, Cerus' stock has faced a downward trend, with a 3.03% drop on the latest trading day, a 3.76% decline for the week, and a steep 16.88% decline month-to-date.

Post-Earnings Price Action Review
A strategy of purchasing Cerus shares immediately after the earnings report and holding for 30 days proved highly ineffective, yielding a return of -66.87%—far below the benchmark of 0.00%. Over a three-year horizon, the compound annual growth rate (CAGR) for the strategy was -31.70%, highlighting the significant underperformance following the earnings announcement.

CEO Commentary
William “Obi” Greenman, President and CEO, highlighted the company’s strong commercial momentum, noting record product sales and a narrowed net loss as positive indicators of progress. He also pointed to the successful early launch of the LED-based INT200 device and ongoing clinical milestones such as the RBC CE Mark resubmission and the CRYO-First study as key drivers for future growth.

Guidance
Cerus raised its full-year 2025 product revenue guidance to a range of $200 million to $203 million, reflecting confidence in continued sales momentum and operational improvements.

Additional News
On June 30, 2025, Cerus Corporation announced its Second Quarter 2025 results, emphasizing its ongoing commitment to blood safety solutions through its global INTERCEPT platform. While no M&A activity was disclosed, the company reiterated its focus on product development and regulatory milestones across its key markets. The CEO reaffirmed the strategic direction centered on the expansion of its INTERCEPT Blood System, including specialized applications for cryoprecipitation and pathogen inactivation. No dividend or share repurchase programs were announced during the period, with management instead prioritizing reinvestment in R&D and market expansion.